Edwards Lifesciences (EW) has updated its fiscal year 2025 financial outlook, projecting a revenue increase of 9% to 10% and showcasing strong financial health with robust margins. The company, a leader in medical devices specializing in structural heart disease treatments, provided this revised guidance at its annual investor conference. Despite positive analyst sentiment and strong financial indicators, a P/E ratio close to its 1-year high and recent insider selling activity suggest a mixed valuation picture.

愛德華生命科學

<p>愛德華生命科學 (EW) 更新了其 2025 財年的財務展望，預計收入增長 9% 至 10%，並展示了強勁的財務健康狀況和穩健的利潤率。該公司是專注於結構性心臟病治療的醫療設備領域的領導者，在其年度投資者會議上提供了這一修訂後的指引。儘管分析師情緒積極且財務指標強勁，但接近一年高點的市盈率和近期的內部人士賣出活動則暗示出一種混合的估值狀況</p>

愛德華生命科學（EW）上調了 2025 財年的收入預測